Skip to content

Amphia Premature Infant Pain Study

Amphia Premature Infant Pain Study; Breast Milk vs Sucrose

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01276366
Acronym
APIP
Enrollment
75
Registered
2011-01-13
Start date
2010-01-01
Completion date
2012-04-01
Last updated
2019-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Feeding, Exclusive, Premature Infant, Puncture Skin

Keywords

Heel lance, Premature, Breast milk

Brief summary

Last thirty years, many research was performed concerning pain in the newborn. These investigations showed us the negative effects of pain in the neonatal period. Our research concerns the choice of analgesics for the premature newborn during a heel lance. Newborns with a gestational age of 32-37 weeks are randomly assigned over three groups. They can receive breastfeeding, during the heel lance, a bottle with supplemental breast milk or sucrose. The primary objective of the Amphia Premature Infant Pain study, is to investigate whether there is a difference in PIPP-scores in premature newborns who undergo a heel lance, receiving breast milk or sucrose. Our hypothesis is that the PIPP-score will be lower in newborns receiving breast milk compared to sucrose. And the investigators presume that breast feeding has the same analgesic effect as giving supplemental breast milk.

Interventions

OTHERsupplemental breast milk

In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.

OTHERbreast feeding

Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.

OTHERsucrose

In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.

Sponsors

Amphia Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 2 Months
Healthy volunteers
Yes

Inclusion criteria

* born at a gestational age between 32+0 and 36+6 weeks, * being nourished with breast milk * the necessity for a clinical blood sample.

Exclusion criteria

* perinatal asphyxia, * birth trauma, * condition of cardio-respiratory instability, * condition of serious nutritional problems with clinical evidence of gastro oesophageal reflux disease, * drug abuse of the mother * and application of sedative medication to mother or child.

Design outcomes

Primary

MeasureTime frameDescription
Pain scores assessed by the PIPP scoreThe PIPP score will be assessed during a heellance. This heellance will be performed after one day of life and before two months.The primary outcome in this trial is the PIPP-score.The PIPP-score is a multidimensional pain assessment measure developed in 1995 . The PIPP-score is validated for procedural and post-operative pain in premature and term newborns.

Secondary

MeasureTime frameDescription
Pain score assessed by the COMFORTneo scoreThe COMFORTneo score will be assessed during a heellance. This heellance will be performed after one day of life and before two months.The COMFORTneo is a secondary outcome.The COMFORTneo is a pain assessment measure modified from the COMFORT behaviour scale. In 2009 the COMFORTneo is validated for prolonged pain. The COMFORTneo is not validated for procedural pain yet .
partial correlation between the two pain assessment tools.up to 2 yearsA secondary outcome is the partial correlation between the PIPP-score and the COMFORTneo score for a heellance in babies born with a postconceptional age between 32 and 37 weeks. When all films are observed, the COMFORTneo scores and PIPP scores are evaluated. We measure a partial correlation coefficient between these scores, to compare these two scores.
intra-class correlation coefficientup to 2 yearsThis secondary outcome measure gives us information about the uniformity of the assessment of the films between the three investigators.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026